Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Yang Liu, Weiming MaoDepartment of Cell Biology and Anatomy, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TXAbstract: Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu Y, Mao W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/07f9e9f96f054baf9039654f2ce42a35
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07f9e9f96f054baf9039654f2ce42a35
record_format	dspace
spelling	oai:doaj.org-article:07f9e9f96f054baf9039654f2ce42a352021-12-02T00:18:03ZTafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma1177-54671177-5483https://doaj.org/article/07f9e9f96f054baf9039654f2ce42a352012-12-01T00:00:00Zhttp://www.dovepress.com/tafluprost-once-daily-for-treatment-of-elevated-intraocular-pressure-i-a11812https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Yang Liu, Weiming MaoDepartment of Cell Biology and Anatomy, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TXAbstract: Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.Keywords: tafluprost, prostaglandin analog, glaucoma, intraocular pressure, preservative-free formulationLiu YMao WDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 7-14 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Liu Y Mao W Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
description	Yang Liu, Weiming MaoDepartment of Cell Biology and Anatomy, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TXAbstract: Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.Keywords: tafluprost, prostaglandin analog, glaucoma, intraocular pressure, preservative-free formulation
format	article
author	Liu Y Mao W
author_facet	Liu Y Mao W
author_sort	Liu Y
title	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
title_short	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
title_full	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
title_fullStr	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
title_full_unstemmed	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
title_sort	tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/07f9e9f96f054baf9039654f2ce42a35
work_keys_str_mv	AT liuy tafluprostoncedailyfortreatmentofelevatedintraocularpressureinpatientswithopenangleglaucoma AT maow tafluprostoncedailyfortreatmentofelevatedintraocularpressureinpatientswithopenangleglaucoma
_version_	1718403781113151488

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Ejemplares similares